Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 11Gastrointestinal 4CNS 2Thoracic 1Gynecologic 1Genitourinary 1

Conditions

Uterine Neoplasms 1Uterine Cervical Neoplasms 1Urologic Neoplasms 1Colorectal Neoplasms 1Carcinoma, Non-Small-Cell Lung 1Breast Neoplasms 1Biliary Tract Neoplasms 1

Interventions

pembrolizumab 65Nivolumab 58Magnetic Resonance Spectroscopy 53enzalutamide 39Abiraterone Acetate 37Radiosurgery 36Gemcitabine 35Specimen Handling 32Radiotherapy 32Ipilimumab 32Androgen Antagonists 32Prednisone 31apalutamide 28Cisplatin 28Docetaxel 27Leuprolide 26atezolizumab 25Carboplatin 25durvalumab 23cabozantinib 23darolutamide 20acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide 19olaparib 18Goserelin 17Radiation 16Gonadotropin-Releasing Hormone 16Biopsy 16gallium 68 PSMA-11 15Pluvicto 15avelumab 14

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Active not recruiting × tucatinib × Genitourinary × Clear all
NCT04579380 2025-12-19

Basket Study of Tucatinib and Trastuzumab in Solid Tumors With HER2 Alterations

Seagen Inc.

Phase 2 Active not recruiting
217 enrolled 19 charts
BreastGastrointestinalGenitourinaryGynecologicThoracic

Biliary Tract Neoplasms, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Uterine Cervical Neoplasms, Urologic Neoplasms, Uterine Neoplasms, Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡